- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00589563
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer .
Descripción general del estudio
Estado
Condiciones
- Linfoma
- Síndromes mielodisplásicos
- Leucemia
- Trastornos mieloproliferativos crónicos
- Cáncer de intestino delgado
- Infección
- Mieloma múltiple y neoplasia de células plasmáticas
- Condición precancerosa
- Enfermedad de injerto contra huésped
- Neoplasias mielodisplásicas/mieloproliferativas
- Mielofibrosis secundaria
Intervención / Tratamiento
- Biológico: anti-thymocyte globulin
- Droga: fludarabine phosphate
- Droga: melphalan
- Droga: methotrexate
- Droga: sirolimus
- Droga: tacrolimus
- Procedimiento: allogeneic hematopoietic stem cell transplantation
- Procedimiento: hematopoietic stem cell transplantation
- Procedimiento: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Procedimiento: peripheral blood stem cell transplantation
- Radiación: total-body irradiation
- Droga: cyclophosphamide
- Droga: etoposide
Descripción detallada
OBJECTIVES:
Primary
- To determine the incidence and severity of acute- and chronic-graft-versus-host disease (GVHD) after HLA-matched or -mismatched unrelated donor hematopoietic peripheral blood transplantation in patients with hematologic malignancies scheduled to receive immunosuppressive combination of sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD prophylaxis.
- To determine the safety of this combination in the first six months post-transplant.
Secondary
- To determine the time-to-engraftment, non-relapse mortality rate, overall and disease-free survival, incidence of disease relapse, and incidence of opportunistic infections with this GVHD prophylaxis.
OUTLINE: Patients are stratified according to conditioning regimen (fludarabine phosphate and melphalan vs fractionated total-body irradiation [FTBI] and etoposide vs FTBI and cyclophosphamide) and degree of donor/recipient HLA mismatch (high-risk vs low-risk).
- Conditioning regimen: Patients receive 1 of 3 standard conditioning regimens beginning on day -9 or -8 and continuing to day -1 or 0.
- Peripheral blood stem cell transplantation: Patients receive HLA-matched or mismatched unrelated donor peripheral blood stem cells on day 0.
- Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -3 and then orally when tolerated, oral sirolimus on days -3 and -2, anti-thymocyte globulin IV over 4-8 hours on days -3 to 0, and methotrexate* IV on days 1, 3, and 6. Tacrolimus and sirolimus continue for 3-6 months (with taper).
NOTE: *Only patients with high-risk HLA mismatch receive treatment with methotrexate.
After completion of study therapy, patients are followed periodically for up to 2 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Banner Good Samaritan Medical Center
-
-
California
-
Duarte, California, Estados Unidos, 91010-3000
- City of Hope Comprehensive Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of hematological malignancy including any of the following:
- Non-Hodgkin lymphoma (NHL) in any complete remission (CR) or partial response (PR)
- Hodgkin lymphoma in any CR or PR
Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in any CR
- Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation of conditioning for patients with non-CR AML or ALL
- Myelodysplastic syndromes (MDS) treated or untreated
- Chronic myelogenous leukemia (CML) in chronic or accelerated phase
- Multiple myeloma in any CR or PR
- Chronic lymphocytic leukemia in CR or PR 2 or greater
Myelofibrosis and other myeloproliferative disorders
- Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation
- High-risk disease defined as AML or ALL > CR1, accelerated phase CML, recurrent aggressive lymphoma, or active lymphoproliferative disease at transplant
- Low-risk disease defined as AML or ALL in CR1, chronic phase CML, or low-grade lymphoproliferative disorder with controlled disease at transplant
Must be planning to receive 1 of the following conditioning regimens at City of Hope:
- Fludarabine phosphate and melphalan for patients with hematological malignancies and contraindications for conventional myeloablative regimens due to age, co-morbidity, or previous transplant
- Fractionated total-body irradiation (FTBI) and etoposide for patients with AML and ALL or CML in accelerated phase
- FTBI and cyclophosphamide for patients with NHL, AML, CML, and MDS
Suitable unrelated donor available
- HLA-matched or mismatched
- Peripheral blood stem cells available
- No bone marrow or ex vivo-engineered or processed graft (e.g., CD34-positive, T-cell depletion)
- No uncontrolled CNS disease
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 70-100% or ECOG PS 0-2
- Creatinine < 1.3 mg/dL or creatinine clearance ≥ 70 mL/min
- Ejection fraction > 45%
- Direct bilirubin < 3 times upper limit of normal (ULN)
- ALT and AST < 3 times ULN
- Forced vital capacity, FEV1, and DLCO > 45% of predicted
- Able to cooperate with oral medication intake
- No active donor or recipient serology positive for HIV
- No known contraindication to administration of sirolimus, tacrolimus, or anti-thymocyte globulin
- No active hepatitis B or C
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Concurrent participation in other clinical trials for prevention or treatment of viral, bacterial, or fungal disease allowed provided agents do not interact with agents used in the current study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Fludarabine/Melphalan Conditioning
Fludarabine/Melphalan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis |
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
Melphalan 140 mg/m2 on day -4 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
|
Experimental: FTBI/Cytoxan Conditioning
FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
|
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
60mg/kg on days -5 and -4 from stem cell transplant
|
Experimental: FTBI/Etoposide Conditioning
FTBI/Etoposide Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis |
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose. Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
60mg/kg on day -4 from stem cell transplant
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100
Periodo de tiempo: 100 Days Post Hematopoietic Stem Cell Transplant (HSCT)
|
Patients were evaluated for the development of acute GVHD within the first 100 days post HSCT.
The cumulative incidence of grade II-IV acute GVHD was determined using competing risk analysis.
Competing risks for acute GVHD were death and nonengraftment.
|
100 Days Post Hematopoietic Stem Cell Transplant (HSCT)
|
Severity of Acute GVHD
Periodo de tiempo: 100 Days Post HSCT
|
All patients were considered for the evaluation of the severity of acute GVHD.
|
100 Days Post HSCT
|
Cumulative Incidence of Chronic GVHD
Periodo de tiempo: 2 year point estimate was provided.
|
Patients were evaluated for the development of chronic GVHD from 101 days post HSCT to last contact or documented evidence of the disease.
The cumulative incidence of chronic GVHD was determined using competing risk analysis.
Competing risks for GVHD were death and nonengraftment.
|
2 year point estimate was provided.
|
Severity of Chronic GVHD
Periodo de tiempo: Patients were evaluated until they developed chronic GVHD, a median of 130 days post HSCT
|
All Patients were considered for the evaluation of chronic GVHD severity.
|
Patients were evaluated until they developed chronic GVHD, a median of 130 days post HSCT
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to Absolute Neutrophil Count Recovery (Engraftment)
Periodo de tiempo: Patients were evaluated until neutrophil recovery, a median of 15 days post HSCT
|
Absolute neutrophil count (ANC) recovery is defined as an ANC of ≥ 0.5 x 10^9/L (500/mm3) for three consecutive laboratory values obtained on different days
|
Patients were evaluated until neutrophil recovery, a median of 15 days post HSCT
|
Time to Platelet Count Recovery (Engraftment)
Periodo de tiempo: Patients were evaluated until platelet recovery, a median of 14 days
|
Platelet recovery is defined as the first date of three consecutive laboratory values ≥ 25 x 10^9 L obtained on different days.
|
Patients were evaluated until platelet recovery, a median of 14 days
|
Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation
Periodo de tiempo: Median Follow Up: 28 months (Range: 1-49 months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
|
Median Follow Up: 28 months (Range: 1-49 months)
|
Occurrence of Thrombotic Microangiopathy
Periodo de tiempo: Median Follow Up: 28 Months (Range: 1-49 months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
This is the number of participants who developed TMA.
|
Median Follow Up: 28 Months (Range: 1-49 months)
|
Occurence of Sinusoidal Obstructive Syndrome (SOS)
Periodo de tiempo: Median Follow Up: 28 Months (Range: 1-49 Months)
|
Participants were monitored throughout the trial (median of 28 months) for various infections/complications.
This is the number of participants who developed SOS.
|
Median Follow Up: 28 Months (Range: 1-49 Months)
|
Non-relapse Mortality at 100 Days Post HSCT
Periodo de tiempo: 100 day point estimate was provided
|
Patients were evaluated for non-relapse mortality (NRM) throughout the study.
Non-relapse mortality was considered any death not attributable to relapse or disease progression.
The cumulative incidence of NRM was determined using competing risk analysis.
Competing risks for NRM were death due to disease progression, relapse and nonengraftment.
|
100 day point estimate was provided
|
Non-relapse Mortality at Two Years Post HSCT
Periodo de tiempo: 2 year point estimate was provided.
|
Patients were evaluated for non-relapse mortality (NRM) throughout the study.
Non-relapse mortality was considered any death not attributable to relapse or disease progression.
The cumulative incidence of NRM was determined using competing risk analysis.
Competing risks for NRM were death due to disease progression, relapse and nonengraftment.
|
2 year point estimate was provided.
|
Overall Survival at Two Years Post HSCT
Periodo de tiempo: 2 year point estimate was provided.
|
Patients were evaluated for survival (OS) throughout the study.
Kaplan Meier estiamtes were calculated for overall survival using time from HSCT to death of any cause or for surviving patients last contact date.
|
2 year point estimate was provided.
|
Event Free Survival at Two Years Post HSCT
Periodo de tiempo: 2 year point estimate was provided.
|
Patients were evaluated for event free survival (EFS) throughout the study.
Events were defined as death, relapse, progression, or nonengraftment.
Kaplan Meier estimates were calculated as time from HSCT to event.
|
2 year point estimate was provided.
|
Incidence of Disease Relapse/Progression at 2 Years Post HSCT
Periodo de tiempo: 2 year point estimate was provided.
|
Patients were evaluated for relapse/progression post transplant throughout the study.
The cumulative incidence of relapse/progression was determined using competing risk analysis.
Competing risks for relapse were non-relapse mortality and nonengraftment.
|
2 year point estimate was provided.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Ryotaro Nakamura, MD, City of Hope Comprehensive Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- mielofibrosis primaria
- Linfoma no Hodgkin cutáneo de células T en estadio I
- leucemia linfocítica crónica en estadio I
- infección
- Linfoma difuso de células grandes en adultos en estadio III
- Linfoma inmunoblástico de células grandes en adultos en estadio III
- Linfoma de Burkitt en adultos en estadio III
- linfoma folicular de grado 3 en estadio IV
- Linfoma difuso de células grandes en adultos en estadio IV
- Linfoma inmunoblástico de células grandes en adultos en estadio IV
- Linfoma de Burkitt en adultos en estadio IV
- linfoma folicular grado 3 recurrente
- Linfoma difuso de células grandes en adultos recidivante
- Linfoma inmunoblástico de células grandes en adultos recidivante
- Linfoma de Burkitt en adultos recidivante
- Linfoma infantil de células pequeñas no hendidas en estadio III
- Linfoma infantil de células pequeñas no hendidas en estadio IV
- Linfoma de células pequeñas no hendidas infantil recidivante
- leucemia mielomonocítica crónica
- síndromes mielodisplásicos de novo
- síndromes mielodisplásicos previamente tratados
- síndromes mielodisplásicos secundarios
- leucemia mieloide aguda en adultos con anomalías 11q23 (MLL)
- leucemia mieloide aguda en adultos con inv(16)(p13;q22)
- leucemia mieloide aguda en adultos con t(15;17)(q22;q12)
- leucemia mieloide aguda en adultos con t(16;16)(p13;q22)
- leucemia mieloide aguda en adultos con t(8;21)(q22;q22)
- leucemia mieloide aguda secundaria
- leucemia linfoblástica aguda infantil en remisión
- leucemia mieloide aguda infantil en remisión
- leucemia mielomonocítica juvenil
- leucemia mielógena crónica en fase crónica
- síndromes mielodisplásicos infantiles
- leucemia mieloide aguda recurrente en adultos
- leucemia mieloide aguda del adulto en remisión
- linfoma de Hodgkin adulto recurrente
- Linfoma de Hodgkin infantil recurrente/refractario
- Linfoma difuso de células pequeñas hendidas en adultos recidivante
- Linfoma difuso de células mixtas en adultos recidivante
- leucemia mielógena crónica recidivante
- linfoma folicular de grado 1 en estadio III
- linfoma folicular de grado 2 en estadio III
- linfoma folicular de grado 3 en estadio III
- Linfoma difuso de células pequeñas hendidas en adultos en estadio III
- Linfoma difuso de células mixtas en adultos en estadio III
- linfoma folicular de grado 1 en estadio IV
- linfoma folicular de grado 2 en estadio IV
- Linfoma difuso de células pequeñas hendidas en adultos en estadio IV
- Linfoma difuso de células mixtas en adultos en estadio IV
- linfoma de células del manto en estadio III
- linfoma de células del manto en estadio IV
- mieloma múltiple en estadio II
- mieloma múltiple en estadio III
- Linfoma difuso de células pequeñas hendidas en adultos en estadio I
- linfoma folicular grado 1 recurrente
- linfoma folicular grado 2 recurrente
- Linfoma folicular grado 1 contiguo en estadio II
- Linfoma folicular grado 2 contiguo en estadio II
- Linfoma difuso de células pequeñas hendidas en adultos contiguos en estadio II
- Linfoma folicular grado 1 en estadio II no contiguo
- Linfoma folicular grado 2 no contiguo en estadio II
- Linfoma difuso de células pequeñas hendidas en adultos no contiguos en estadio II
- Linfoma de linfocitos pequeños no contiguos en estadio II
- Linfoma no contiguo de la zona marginal en estadio II
- linfoma de la zona marginal recurrente
- linfoma de linfocitos pequeños recurrente
- Linfoma de linfocitos pequeños en estadio III
- linfoma de la zona marginal en estadio III
- Linfoma de linfocitos pequeños en estadio IV
- linfoma de la zona marginal en estadio IV
- Linfoma contiguo de la zona marginal en estadio II
- Linfoma de linfocitos pequeños contiguos en estadio II
- Linfoma extraganglionar de células B de la zona marginal de tejido linfoide asociado a mucosas
- linfoma de células B de la zona marginal ganglionar
- linfoma esplénico de la zona marginal
- mieloma múltiple en estadio I
- linfoma linfoblástico adulto recurrente
- linfoma de células del manto recurrente
- leucemia linfocítica crónica refractaria
- leucemia linfocítica crónica en estadio II
- leucemia linfocítica crónica en estadio III
- leucemia linfocítica crónica en estadio IV
- Linfoma de Hodgkin en adultos en estadio III
- Linfoma de Hodgkin en adultos en estadio IV
- linfoma no Hodgkin cutáneo de células T en estadio III
- Linfoma no Hodgkin cutáneo de células T en estadio IV
- Linfoma no Hodgkin cutáneo de células T recidivante
- linfoma del intestino delgado
- Linfoma linfoblástico en adultos en estadio III
- Linfoma linfoblástico en adultos en estadio IV
- leucemia/linfoma de células T del adulto en estadio III
- leucemia/linfoma de células T del adulto en estadio IV
- leucemia/linfoma recurrente de células T en adultos
- linfoma angioinmunoblástico de células T
- linfoma anaplásico de células grandes
- Granulomatosis linfomatoide grado III del adulto recurrente
- linfoma no Hodgkin cutáneo de células B
- leucemia linfoblástica aguda recurrente en adultos
- leucemia linfoblástica aguda infantil recurrente
- Linfoma linfoblástico infantil en estadio III
- Linfoma linfoblástico infantil en estadio IV
- Linfoma contiguo de células del manto en estadio II
- Linfoma de células del manto en estadio II no contiguo
- Linfoma no Hodgkin cutáneo de células T en estadio II
- Linfoma difuso de células grandes en adultos no contiguos en estadio II
- Linfoma difuso de células mixtas en adultos no contiguos en estadio II
- Linfoma linfoblástico no contiguo en adultos en estadio II
- Linfoma folicular grado 3 no contiguo en estadio II
- leucemia mielógena crónica en fase acelerada
- leucemia linfoblástica aguda del adulto en remisión
- Linfoma de Hodgkin infantil en estadio IV
- leucemia mieloide aguda infantil recurrente
- neoplasia mielodisplásica/mieloproliferativa, inclasificable
- leucemia mieloide crónica atípica, BCR-ABL negativo
- Linfoma de Burkitt en adultos no contiguos en estadio II
- Linfoma inmunoblástico de células grandes en adultos en estadio II no contiguo
- linfoma linfoblástico infantil recurrente
- Linfoma de Hodgkin infantil en estadio III
- Linfoma de Hodgkin en adultos en estadio I
- Linfoma de Hodgkin en adultos en estadio II
- Linfoma de Burkitt en adultos en estadio I
- Linfoma de Burkitt en adultos contiguos en estadio II
- Linfoma inmunoblástico de células grandes contiguo en estadio II en adultos
- Linfoma inmunoblástico de células grandes en adultos en estadio I
- Linfoma de Hodgkin infantil en estadio I
- Linfoma de Hodgkin infantil en estadio II
- Granulomatosis linfomatoide grado III infantil recurrente
- Linfoma anaplásico de células grandes infantil recidivante
- Linfoma anaplásico de células grandes infantil en estadio III
- Linfoma anaplásico de células grandes infantil en estadio IV
- Linfoma folicular grado 3 contiguo en estadio II
- Linfoma difuso de células grandes en adultos contiguos en estadio II
- Linfoma difuso de células mixtas en adultos contiguos en estadio II
- Linfoma difuso de células grandes en adultos en estadio I
- Linfoma difuso de células mixtas en adultos en estadio I
- leucemia/linfoma de células T del adulto en estadio I
- Linfoma linfoblástico contiguo en estadio II en adultos
- Linfoma linfoblástico en adultos en estadio I
- Linfoma de Burkitt
- Enfermedad de injerto contra huésped
- linfoma de Hodgkin de pronóstico favorable en adultos
- linfoma de Hodgkin de pronóstico desfavorable en adultos
- mielofibrosis secundaria
- linfoma de Hodgkin infantil de pronóstico desfavorable
- childhood favorable prognosis Hodgkin lymphoma
- Granulomatosis linfomatoide grado I recurrente
- Granulomatosis linfomatoide grado II recurrente
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Neoplasias por sitio
- Enfermedad
- Enfermedades de la médula ósea
- Enfermedades hematológicas
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Trastornos hemorrágicos
- Enfermedades intestinales
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Procesos Neoplásicos
- Neoplasias
- Linfoma
- Síndrome
- Síndromes mielodisplásicos
- Mielofibrosis primaria
- Mieloma múltiple
- Neoplasias De Células Plasmáticas
- Leucemia
- Metástasis de neoplasias
- Preleucemia
- Plasmacitoma
- Neoplasias Intestinales
- Trastornos mieloproliferativos
- Enfermedades mielodisplásicas-mieloproliferativas
- Enfermedad de injerto contra huésped
- Condiciones precancerosas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Agentes antineoplásicos, fitogénicos
- Inhibidores de la topoisomerasa II
- Inhibidores de la topoisomerasa
- Agentes dermatológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Agentes de control reproductivo
- Agentes abortivos, no esteroideos
- Agentes abortivos
- Antagonistas del ácido fólico
- Inhibidores de calcineurina
- Ciclofosfamida
- Etopósido
- Melfalán
- Fludarabina
- Fosfato de fludarabina
- Metotrexato
- Tacrolimus
- Sirolimus
- Suero Antilinfocito
Otros números de identificación del estudio
- 06141
- P30CA033572 (Subvención/contrato del NIH de EE. UU.)
- CHNMC-06141
- CDR0000579340 (Identificador de registro: NCI PDQ)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre anti-thymocyte globulin
-
Prometic Biotherapeutics, Inc.Atlantic Research GroupTerminadoInmunodeficiencia PrimariaEstados Unidos
-
Beijing Doing Biomedical Co., Ltd.Aún no reclutandoLinfoma | LeucemiaPorcelana
-
Johns Hopkins UniversityTerminadoDegeneración macular húmeda | Degeneración macular relacionada con la edad neovascular | Hemorragia submacularEstados Unidos
-
University of LeipzigDesconocidoEdema macular diabético | Edema macular | Oclusión de la vena retinalAlemania
-
Symphogen A/STerminadoLinfoma | Tumor solido | Cáncer metastásicoCanadá, Estados Unidos
-
Shanghai Huaota Biopharmaceutical Co., Ltd.ReclutamientoNSCLC | Tumor sólido avanzadoEstados Unidos, Porcelana
-
The First Affiliated Hospital of Soochow UniversityReclutamientoSeguridad y EficaciaPorcelana
-
Affiliated Hospital to Academy of Military Medical...DesconocidoLinfoma | LeucemiaPorcelana
-
Sohag UniversityReclutamientoLupus eritematoso sistémicoEgipto
-
Proclara Biosciences, Inc.Alzheimer's AssociationTerminadoEnfermedad de AlzheimerEstados Unidos